Blog
RSS FeedPosted by Michael Wonder on 01 May 2019
NHS England finalises procurement to eliminate hepatitis C
1 May 2019 - After lengthy negotiations and a court battle, NHS England has reached agreement with three drug companies ...
Posted by Michael Wonder on 30 Sep 2016
AbbVie's investigational HCV regimen receives U.S. FDA breakthrough therapy designation
30 September 2016 - Breakthrough therapy designation granted based on Phase 2 clinical data for genotype 1 patients who failed previous ...
Posted by Michael Wonder on 23 Sep 2016
NICE says yes to another hepatitis C drug
23 September 2016 - A new drug which effectively treats more genotypes of hepatitis C has been recommended for use in ...
Posted by Michael Wonder on 09 Sep 2016
More options to be made available to treat hepatitis C
9 September 2016 - Another ‘potential curative’ drug for people with chronic hepatitis C will be made available on the NHS. ...
Posted by Michael Wonder on 31 Aug 2016
TGA approves Zepatier
31 August 2016 - The TGA has approved MSD's Zepatier (grazoprevir with elbasvir). ...
Posted by Michael Wonder on 08 Aug 2016
New FDA documents reveal history of breakthrough therapy designation for Epclusa
5 August 2016 - Sofosbuvir with velpatasvir was originally granted fast track designation by the FDA on 30 September 2013 ...
Posted by Michael Wonder on 30 Jul 2016
A pill too hard to swallow: how the NHS is limiting access to high priced drugs
27 July 2016 - A joint investigation by The BMJ and Cambridge and Bath universities uncovers how NHS England tried to ...
Posted by Michael Wonder on 30 Jul 2016
High cost of new drugs
27 July 2016 - Why government must negotiate a better deal for publicly funded research. ...
Posted by Michael Wonder on 30 Jul 2016
Hollow victories and hepatitis C
28 July 2016 - When Gilead Sciences introduced sofosbuvir based antivirals in 2014, the drugs were touted as a breakthrough for ...
Posted by Michael Wonder on 28 Jul 2016
Betting on hepatitis C: how financial speculation in drug development influences access to medicines
27 July 2016 - Victor Roy and Lawrence King argue that the acquisition strategies of drug companies magnify development costs and ...
Posted by Michael Wonder on 28 Jul 2016
NHS 'abandoning' thousands by rationing hepatitis C drugs
28 July 2016 - Addaction says NHS England decision to treat just 10,000 people a year with costly drugs is ‘potential ...
Posted by Michael Wonder on 28 Jul 2016
EMA publishes EPAR for Zepatier (grazoprevir with elbasvir)
28 July 2016 - The EMA has published an EPAR for Merck's Zepatier. ...
Posted by Michael Wonder on 28 Jul 2016
EMA publishes EPAR for Epclusa (sofosbuvir with velpatasvir)
28 July 2016 - The EMA has published an EPAR for Gilead's Epclusa. ...
Posted by Michael Wonder on 26 Jul 2016
CADTH recommends reimbursement of Sunvepra
20 July 2016 - CADTH has recommended that asunaprevir (Sunvepra) be reimbursed in Canada. ...
Posted by Michael Wonder on 25 Jul 2016
AbbVie receives U.S. FDA approval of once daily Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the treatment of genotype 1 chronic hepatitis C
25 July 2016 - New extended-release formulation is the first all-oral, co-formulated treatment containing the three direct-acting antiviral components of Viekira ...